Assessment of lymph node metastasis in pancreatic ductal adenocarcinoma using extracellular volume fraction
10.3969/j.issn.1673-9701.2024.26.009
- VernacularTitle:细胞外容积分数评估胰腺导管腺癌淋巴结转移
- Author:
Ruru GAO
1
;
Zenghua ZHENG
;
Xuan QIN
;
Jianbing MA
;
Jun HAN
;
Jian DING
;
Xiang ZHU
Author Information
1. 嘉兴市第一医院放射科,浙江嘉兴 314000
- Keywords:
Pancreatic ductal adenocarcinoma;
CT value;
Extracellular volume fraction;
Lymph node metastasis
- From:
China Modern Doctor
2024;62(26):38-40,45
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the diagnostic efficacy of extracellular volume fraction(fECV)based on multi-slice spiral CT in evaluating lymph node metastasis of pancreatic ductal adenocarcinoma.Methods A total of 74 patients diagnosed as pancreatic ductal adenocarcinoma from March 2018 to March 2023 in the First Hospital of Jiaxing were retrospectively collected.All patients underwent enhanced multi-slice spiral CT examination.Hematocrit was collected before examination.CT values at the plain phase,portal phase,the equilibrium phase of the lesion and CT values of abdominal aorta at the same level were respectively measured after examination,and fECV was calculated.Using postoperative pathological results as the"gold standard",the efficacy of fECV in diagnosing lymph node metastases of pancreatic ductal adenocarcinoma was evaluated by receiver operating characteristic curve.Results There were 33 cases with lymph node metastasis in positive group and 41 cases in negative group.There was no statistically significant difference in fECV at the portal phase between lymph node metastasis positive group and negative group(t=0.80,P＞0.05).There was statistically significant difference in fECV at the equilibrium phase between positive and negative lymph node metastasis group(t=2.84,P＜0.001).The area under the curve of lymph node metastasis in portal phase and equilibrium phase were 0.517 and 0.870,respectively.Conclusion The fECV based on multi-slice spiral CT equilibrium phase can evaluate lymph node metastasis of pancreatic ductal adenocarcinoma.
